Table 4.
Smoking cessation outcomes (predictors based on FMC purchase task) | EC use outcomes (predictors based on EC purchase task) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Quit status | Relapse status | Any use between waves |
EC purchase between waves |
Past 30 Days Use | ||||||
OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
Intensity | .97* | (.94–.99) | 1.05** | (1.02–1.10) | 1.03* | (1.01–1.05) | 1.02 | (.99–1.06) | 1.02 | (.98–1.07) |
Pmax | .99 | (.81–1.22) | 1.05 | (.82–1.35) | 1.45* | (1.05–1.99) | 1.85** | (1.25–2.72) | 2.01** | (1.23–3.30) |
Breakpoint | .89 | (.74–1.06) | 1.19 | (.96–1.49) | 1.19* | (1.02–1.38) | 1.28* | (1.05–1.57) | 1.36* | (1.05–1.77) |
Essential value | .45* | (.21-.97) | 2.55 | (.98–6.63) | 3.96** | (1.46–10.70) | 6.63** | (1.68–26.14) | 6.34* | (1.09–36.75) |
Data from daily smokers in the Netherlands collected in April 2014 and July 2015.
Quit Status sample size: n = 782
Relapse Status sample size: n = 242
EC Use sample size: n = 645
Adjusted models included: sex, age, roll-your-own smoking status, motivation to quit, and heaviness of smoking index; cessation outcomes also included baseline EC use in the past 30 days
*p < .05; **p < .01